These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Combined Fc-protein- and Fc-glyco-engineering of scFv-Fc fusion proteins synergistically enhances CD16a binding but does not further enhance NK-cell mediated ADCC. Repp R, Kellner C, Muskulus A, Staudinger M, Nodehi SM, Glorius P, Akramiene D, Dechant M, Fey GH, van Berkel PH, van de Winkel JG, Parren PW, Valerius T, Gramatzki M, Peipp M. J Immunol Methods; 2011 Oct 28; 373(1-2):67-78. PubMed ID: 21855548 [Abstract] [Full Text] [Related]
4. scFv-based "Grababody" as a general strategy to improve recruitment of immune effector cells to antibody-targeted tumors. Cai Z, Fu T, Nagai Y, Lam L, Yee M, Zhu Z, Zhang H. Cancer Res; 2013 Apr 15; 73(8):2619-27. PubMed ID: 23396586 [Abstract] [Full Text] [Related]
14. Correlation between CD16a binding and immuno effector functionality of an antigen specific immunoglobulin Fc fragment (Fcab). Kainer M, Antes B, Wiederkum S, Wozniak-Knopp G, Bauer A, Rüker F, Woisetschläger M. Arch Biochem Biophys; 2012 Oct 15; 526(2):154-8. PubMed ID: 22634259 [Abstract] [Full Text] [Related]
15. CD96 is a leukemic stem cell-specific marker in human acute myeloid leukemia. Hosen N, Park CY, Tatsumi N, Oji Y, Sugiyama H, Gramatzki M, Krensky AM, Weissman IL. Proc Natl Acad Sci U S A; 2007 Jun 26; 104(26):11008-13. PubMed ID: 17576927 [Abstract] [Full Text] [Related]